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ABSTRACT
Epstein-Barr virus (EBV) infects most of the world’s population and is causally associated with several human cancers, but little
is known about how EBV genetic variation might influence infection or EBV-associated disease. There are currently no pub-
lished wild-type EBV genome sequences from a healthy individual and very few genomes from EBV-associated diseases. We have
sequenced 71 geographically distinct EBV strains from cell lines, multiple types of primary tumor, and blood samples and the
first EBV genome from the saliva of a healthy carrier. We show that the established genome map of EBV accurately represents all
strains sequenced, but novel deletions are present in a few isolates. We have increased the number of type 2 EBV genomes se-
quenced from one to 12 and establish that the type 1/type 2 classification is a major feature of EBV genome variation, defined
almost exclusively by variation of EBNA2 and EBNA3 genes, but geographic variation is also present. Single nucleotide polymor-
phism (SNP) density varies substantially across all known open reading frames and is highest in latency-associated genes. Some
T-cell epitope sequences in EBNA3 genes show extensive variation across strains, and we identify codons under positive selec-
tion, both important considerations for the development of vaccines and T-cell therapy. We also provide new evidence for re-
combination between strains, which provides a further mechanism for the generation of diversity. Our results provide the first
global view of EBV sequence variation and demonstrate an effective method for sequencing large numbers of genomes to further
understand the genetics of EBV infection.
IMPORTANCE
Most people in the world are infected by Epstein-Barr virus (EBV), and it causes several human diseases, which occur at very dif-
ferent rates in different parts of the world and are linked to host immune system variation. Natural variation in EBV DNA se-
quence may be important for normal infection and for causing disease. Here we used rapid, cost-effective sequencing to deter-
mine 71 new EBV sequences from different sample types and locations worldwide. We showed geographic variation in EBV
genomes and identified the most variable parts of the genome. We identified protein sequences that seem to have been selected
by the host immune system and detected variability in known immune epitopes. This gives the first overview of EBV genome
variation, important for designing vaccines and immune therapy for EBV, and provides techniques to investigate relationships
between viral sequence variation and EBV-associated diseases.
Epstein-Barr virus (EBV) infects about 90% of the world’s pop-ulation and plays a role in many human diseases. EBV persists
latently in infected B cells for the lifetime of the infected individ-
ual, residing as a multicopy episome and replicating with each cell
division. EBV causes infectious mononucleosis and is causally as-
sociated with several types of cancer, including endemic Burkitt
lymphoma (BL), nasopharyngeal carcinoma (NPC), 30% of
Hodgkin lymphoma cases, 10% of gastric carcinoma cases, and
some cases of diffuse large B-cell lymphoma (DLBCL) and leio-
myosarcoma (1). In immunosuppressed individuals, the ability of
EBV to cause long-term proliferation of infected B cells results in
immunoblastic lymphomas, the main cause of EBV disease in
transplant patients (2). In total, EBV is associated with approxi-
mately 1.5% of human cancers worldwide. Furthermore, epide-
miological evidence points to the involvement of EBV in the au-
toimmune disorders multiple sclerosis and systemic lupus
erythematosus (2).
Some diseases associated with EBV have notably different in-
cidence rates throughout the world; NPC is exceptionally frequent
in southern China, and endemic BL is very frequent in sub-Saha-
ran Africa, where malaria is hyperendemic (1). Many factors are
likely to contribute to the incidence of EBV-associated diseases in
different geographic populations, although the role of EBV se-
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quence variation is not yet well defined. It is known that EBV
genome variation can contribute to lymphomagenesis; deletion of
the EBNA3B gene enhances EBV tumorigenicity in a mouse
model reconstituted with the human immune system from hema-
topoietic stem cells (3). The tumors arising in those mice resem-
bled DLBCL, and some human DLBCL cases contain EBV with a
deletion or disruption of the EBNA3B gene. EBV genome varia-
tion has also been observed in Burkitt lymphomas, where approx-
imately 10% of tumors contain EBV with a deletion of EBNA2 and
the C-terminal exons of EBNA-LP (4). This suggests that EBV
variants may differ in their ability to cause disease, although it is
not known if such variants are transmissible between individuals
or arise spontaneously within an individual and are not transmis-
sible. Since the establishment of lifelong persistence of EBV might
involve the transit of infected B cells through germinal centers
(where the enzyme activation-induced cytidine deaminase [AID]
promotes DNA mutation), the potential exists for EBV genome
variants to arise during long-term infection. To investigate the
potential for genome variation in EBV to affect the phenotype of
different strains, a more extensive analysis of EBV genomes is
required. Efforts to produce successful EBV vaccines (5) will also
depend on ensuring that the vaccines are directed against the se-
quence of currently circulating isolates. Understanding more
about EBV sequence variation in normal infection and disease is
thus of considerable interest.
There are known differences in phenotypic properties between
EBV isolates. B95-8 EBV lacks some of the BART miRNA genes
and one of the origins of lytic replication (6) but efficiently estab-
lishes lymphoblastoid cell lines (LCLs) from peripheral blood B
cells, whereas M81 EBV (derived originally from an NPC) is more
efficient at infecting epithelial cells and gives a higher frequency of
spontaneous lytic virus replication (7). EBV strains have been
classified into type 1 and type 2 (also known as types A and B,
respectively) based primarily on the sequence of their EBNA2
gene (1), with the EBNA2 protein sequence of the type 1 reference
strain having only 56% identity to type 2 EBNA2. The extent of
variation elsewhere in the genome between EBV type 1 and 2 is not
well established, as only one type 2 EBV full genome sequence
(AG876) has been published (8). Type 1/type 2 variation in the
EBNA3 family of genes is generally linked to the EBNA2 variation
(9, 10), although intertypic recombinants have been identified
(11–13), and some linkage of EBNA-LP variation has also been
proposed. Type 1 EBV strains are prevalent worldwide, but in
parts of sub-Saharan Africa, type 2 is equally prevalent. The main
phenotypic difference is that type 1 EBV transforms human
B-lymphocytes into LCLs more efficiently (14). The LMP1 gene
has been classified into 7 sequence variants, with some evidence
for sequence variation affecting its cell transformation proper-
ties (15, 16). Other studies of polymorphisms in EBV genes
have been summarized recently (15). However, too few EBV
whole-genome sequences have been determined to investigate
the range and frequency of disease and geographically associ-
ated genome variation.
The first complete EBV genome sequence, B95-8, was pub-
lished in 1984 (6). Since then, genome sequences of 22 additional
EBVs have been reported (AG876, GD1, GD2, HKNPC1, Akata,
Mutu, C666-1, M81, Raji, K4123-Mi, and K4413-Mi), as well as
eight NPC EBV sequences and three EBV genomes derived from
the 1000 Genomes project (7, 8, 17–24). Recently, we and others
have described herpesvirus sequencing strategies using a genome
capture method analogous to human exome sequencing (18, 25).
In addition to the sequencing itself, methods of assembling, anno-
tating, and analyzing the 170-kb EBV genomes have also been
established. We have successfully applied these methods to a large
set of available EBV isolates, and we describe 71 new EBV genomes
from different locations around the world; a combined analysis of
these alongside 12 previously published sequences provides the
first opportunity to test the general validity of the EBV genetic
map and explore recombination, geographic variation, and the
major features of variation in this virus.
MATERIALS AND METHODS
Virus strains. DNA samples from cell lines and primary tumor biopsy
material for sequencing were provided by Paul Farrell, Martin Allday, and
Robert White at Imperial College London, Paul Murray, Alan Rickinson,
and John Arrand at the University of Birmingham, and Lawrence Young
at the University of Warwick. Sample names, EBNA2 types, and geo-
graphic origins are listed in Table 1. The Saliva1 sample (2 ml) was col-
lected from a healthy individual in the United Kingdom using an Oragene
saliva kit (Labtech), and DNA was extracted directly from the kit accord-
ing to the manufacturer’s instructions.
Virus load. Virus load was measured by real-time PCR of a 78-bp
amplicon spanning the intron between exons W1 and W2 of EBNA-LP
within the major internal repeat of EBV. Samples were prepared with the
SensiMix dU kit (Bioline) using a 5 mM MgCl2 concentration, forward
and reverse primers at a 20 pM final concentration (forward primer, 5=
GGCCAGAGGTAAGTGGACTTTAAT 3=; reverse primer, 5= GGGGAC
CCTGAGACGGG 3=), and a probe at a 10 pM final concentration (5=
FAM-CCCAACACTCCACCACACCCAGGC-BHQ1 3=). Quantitative
PCR was performed on a Masterplex thermocycler ep (Eppendorf) with
an initial 15-min incubation at 95°C followed by 45 cycles at 95°C for 15 s
and 60°C for 60 s. Threshold cycle (CT) values were compared to a stan-
dard curve generated using a B95-8 plasmid target to assign a copy num-
ber per microliter. Samples with more than 106 total genome copies were
sequenced.
Bait design. Overlapping 120-mer RNA baits spanning the length of
the reference genomes (accession numbers NC_007605 and NC_009334
for type 1 and type 2 EBV, respectively) were designed using eArray soft-
ware (Agilent Technologies). Baits were designed so that each nucleotide
was covered by 5 different bait sequences, leading to a total of 7,154 probes
covering type 1 EBV and 7,193 covering type 2 EBV with a new bait every
24 bp of the genome. Bait libraries were synthesized by Agilent Technol-
ogies.
Target enrichment and sequencing. One to three micrograms of each
DNA sample was sheared to 200- to 400-bp fragments using a Covaris
E210 sonicator (Covaris Inc.). End repair, nontemplated addition of 3=-A,
adaptor ligation, hybridization, enrichment PCR, and all postreaction
cleanup steps were performed according to the SureSelect Illumina
paired-end sequencing library protocol (version 1.1). Samples were mul-
tiplexed (6 to 25 samples per lane on an 8-lane flow cell), and cluster
generation and sequencing were performed using an Illumina HiSeq 2000
sequencer. Sequencing reads were 76-bp paired-end reads in FASTQ for-
mat with per-base Phred quality scores.
Genome assembly. All read pairs were subjected to stringent quality
control using the QUASR (http://sourceforge.net/projects/quasr) QC
pipeline (26) to remove duplicate read pairs and to remove paired reads if
either read had a raw median Phred quality score below 32 or were trimmed
from the 3=end until the median Phred score was32. Any reads less than 50
bp in length after trimming were discarded. The remaining quality controlled
read pairs were assembled using the VelvetOptimiser (v2.2.4) script (http:
//www.vicbioinformatics.com/software.velvetoptimiser.shtml), which scans
different parameters in the Velvet (v. 1.2.07) de novo assembler (27) to
optimize the assembly. Contigs generated by Velvet were oriented to the
reference genome (NC_007605 for type 1 or NC_009334 for type 2) using
Abacas (v1.3.1) (28), and gap filling and contig extension were performed
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TABLE 1 List of samples sequenced and the 12 published sequences analyzeda
Sample
no. Name Type
Geographic
origin
EBNA2
type Reference
SRA accession
no.
GenBank
accession no.
1 B95.8 (Raji) IM USA 1 6 NC_007605
B95.8 V01555
2 AG876 BL Ghana 2 8 NC_009334
3 GD1 NPC—saliva China 1 24 AY961628
4 GD2 NPC—tumor China 1 21 HQ020558
5 HKNPC1 NPC—tumor Hong Kong 1 17 JQ009376
6 Akata BL Japan 1 20 KC207813
7 Mutu BL Kenya 1 20 KC207814
8 C666-1 NPC China 1 23 KC617875
9 K4123-Mi sLCL USA 1 19 KC440851
10 K4413-Mi sLCL USA 1 19 KC440852
11 M81 NPC Hong Kong 1 7 KF373730
12 Raji BL Nigeria 1 Unpublishedb KF717093
13 Saliva1 Healthy saliva UK 1 ERS074900 LN824142
14 HL01 HL UK 1 ERS549508 LN824226
15 HL02 HL UK 1 ERS549509 LN827546
16 HL04 HL UK 1 ERS549511 LN827564
17 HL05 HL UK 1 ERS549512 LN824204
18 HL08 HL UK 1 ERS549513 LN824225
19 HL09 HL UK 1 ERS549514 LN827522
20 HL11 HL UK 1 ERS549515 LN827524
21 L591 HL cell line Germany 1 ERS549506 LN827523
22 YCCEL1 GC cell line South Korea 1 ERS549504 LN827561
23 Wewak1 BL PNG 2 ERS074939 LN827544
24 AFB1 LCL Unknown 2 ERS549470 LN827554
25 HKN14 sLCL Hong Kong 1 ERS549501 LN824209
26 HKN15 sLCL Hong Kong 1 ERS549502 LN827547
27 HKN19 sLCL Hong Kong 1 ERS549503 LN824224
28 D3201.2 NPC biopsy China 1 ERS549507 LN827549
29 C666-1 resequence NPC cell line China 1 ERS549471 LN827525
30 M-ABA LCL, NPC virus N. Africa 1 ERS074943 LN827527
31 Akata resequence BL Japan 1 ERS074927 LN824208
32 Jijoye BL Nigeria 2 ERS074941 LN827800
33 P3HR1 c16 BL Nigeria 2 ERS074940 LN827548
34 Cheptages BL Kenya 2 ERS074945 LN827556
35 Daudi BL Kenya 1 ERS074946 LN827545
36 BL36 BL N. Africa 1 ERS549475 LN827557
37 BL37 BL Africa 1 ERS549473 LN827526
38 Makau BL Kenya 1 ERS549472 LN827551
39 Mak1 duplicate BL Kenya 1 ERS074936 LN824203
40 sLCL-IM1.02 sLCL, IM Australia 1 ERS074911 LN827596
41 sLCL-IM1.05 sLCL, IM Australia 1 ERS074912 LN827590
42 sLCL-IM1.09 sLCL, IM Australia 1 ERS074929 LN827567
43 sLCL-IM1.16 sLCL, IM Australia 1 ERS074925 LN827799
44 sLCL-IM1.17 sLCL, IM Australia 1 ERS074932 LN827583
45 sLCL-IS1.01 sLCL, PTLD Australia 1 ERS074914 LN827570
46 sLCL-IS1.03 sLCL, PTLD Australia 1 ERS074915 LN827595
47 sLCL-IS1.04 sLCL, PTLD Australia 1 ERS074923 LN827597
48 sLCL-IS1.06 sLCL, PTLD Australia 1 ERS074916 LN827584
49 sLCL-IS1.07 sLCL, PTLD Australia 1 ERS074926 LN827594
50 sLCL-IS1.08 sLCL, PTLD Australia 1 ERS074917 LN827553
51 sLCL-IS1.10 sLCL, PTLD Australia 1 ERS074918 LN827592
52 sLCL-IS1.11 sLCL, PTLD Australia 1 ERS074919 LN827569
53 sLCL-IS1.12 sLCL, PTLD Australia 1 ERS074930 LN827593
54 sLCL-IS1.13 sLCL, PTLD Australia 1 ERS074913 LN827578
55 sLCL-IS1.14 sLCL, PTLD Australia 1 ERS074931 LN827575
56 sLCL-IS1.15 sLCL, PTLD Australia 1 ERS074927 LN827586
57 sLCL-IS1.18 sLCL, PTLD Australia 1 ERS074920 LN827572
58 sLCL-IS1.19 sLCL, PTLD Australia 1 ERS074925 LN827588
(Continued on following page)
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computationally using IMAGE (29) and GapFiller (30). Improved contigs
were again oriented to the appropriate reference genome using Abacas.
The raw sequencing reads were mapped back to the oriented contigs and
checked manually for misassemblies.
PCR gap filling and verification of de novo assemblies. For genome
regions that could not be finished computationally, PCR and capillary
sequencing was used. Primer sequences and annealing temperatures used
for PCR and sequencing are listed in Table SA1 in the supplemental ma-
terial. PCR was performed using a Platinum Taq DNA polymerase high-
fidelity kit (Invitrogen), and cycling conditions were as follows: 95°C for 3
min, 30 cycles of 94°C for 20 s, the specific primer annealing temperature
(see Table SA1) for 30 s, and 68°C for 3 min, and a final extension at 68°C
for 7 min. PCR with primers U005 and U006 was performed using the
KAPA 2G Robust PCR kit with deoxynucleoside triphosphate s (dNTPs)
(Kapa Biosystems) using GC-rich buffer and the following cycling condi-
tions: 98°C for 3 min, 25 cycles of 98°C for 30 s, the specific primer
annealing temperature for 30 s, and 72°C for 2 min, and a final extension
of 72°C for 2 min. PCR products were sequenced on an ABI 3730 capillary
sequencer. The same primers were used for sequencing except where
noted. PCR products were merged into the de novo genome assembly
using Gap5 software (31) to generate a final genome sequence for each
strain. Regions where PCR failed or which could not be fully resolved were
filled with Ns.
Estimation of IR1 repeat size. Southern blotting using a probe to IR1
containing BamHI W (positions 13215 to 16287 of NC_007605) was used
to estimate by size the copy number of the IR1 repeat in a subset of virus
strains. Cell line DNA was digested with KpnI and analyzed by Southern
blotting, using a depurination step to aid transfer of the large restriction
fragments. The unique region sequences allowed correction for variation
in KpnI sites in the EBV genomes. Depth of sequencing was also used to
estimate the number of copies of the IR1 repeat, and the results from both
methods were compared. The short reads from each sample were mapped
to a single copy of the IR1 repeat (3,071 bp; sequence taken from the B95-8
reference genome, NC_007605) using the Burrows-Wheeler aligner
(BWA) (32), and the average depth of coverage was calculated using
SAMTools (33). Reads were also mapped to a single-copy gene
(BALF5) to estimate the genome coverage in nonrepetitive parts of the
genome. The average depth of the IR1 mapping was normalized to the
average depth of BALF5 to estimate the number of copies of the IR1
repeat in each sequence.
Genome alignments, SNP calling, and phylogenetics. A map of the
geographic origins of the samples was generated using Tableau software
(v8.8.2). Sequence alignments were generated using MAFFT (v7.0) and
EMBOSS Stretcher (v6.6) and parsed using Biopython (34). Repeat re-
gions were masked across the whole alignment using the coordinates of
the repeat regions in the NC_007605 reference sequence annotation. Sin-
gle nucleotide polymorphisms (SNPs) between genomes were counted
relative to a consensus sequence derived from the multiple-sequence
alignment. LMP1 types were assigned manually from a multiple-sequence
alignment of LMP1 protein sequences according to the types defined pre-
viously (16). Model selection on an LMP1 nucleotide alignment was per-
formed using jModelTest (v2.1.5) (35), and the most appropriate model
was a general time-reversible model of nucleotide substitution, with
gamma-distributed among-site rate heterogeneity and a category of in-
TABLE 1 (Continued)
Sample
no. Name Type
Geographic
origin
EBNA2
type Reference
SRA accession
no.
GenBank
accession no.
59 sLCL-IS1.20 sLCL, PTLD Australia 1 ERS074926 LN827576
60 sLCL-IS2.01 sLCL, PTLD Australia 2 ERS074928 LN827589
61 sLCL-1.02 sLCL Kenya 1 ERS549478 LN827558
62 sLCL-BL1.03 sLCL Kenya 1 ERS549479 LN827582
63 sLCL-1.04 sLCL Kenya 1 ERS549480 LN827585
64 sLCL-1.05 sLCL Kenya 1 ERS549481 LN827581
65 sLCL-1.06 sLCL Kenya 1 ERS549482 LN827566
66 sLCL-1.07 sLCL Kenya 1 ERS549483 LN827565
67 sLCL-1.08 sLCL Kenya 1 ERS549484 LN827552
68 sLCL-1.09 sLCL Kenya 1 ERS549485 LN827574
69 sLCL-1.10 sLCL Kenya 1 ERS549486 LN827573
70 sLCL-1.11 sLCL Kenya 1 ERS549487 LN827550
71 sLCL-1.12 sLCL Kenya 1 ERS549488 LN824205
72 sLCL-1.13 sLCL Kenya 1 ERS549489 LN827579
73 sLCL-2.14 sLCL Kenya 2 ERS549490 LN827560
74 sLCL-2.15 sLCL Kenya 2 ERS549491 LN827591
75 sLCL-2.16 sLCL Kenya 2 ERS549492 LN827580
76 sLCL-1.17 sLCL Kenya 1 ERS549493 LN827577
77 sLCL-1.18 sLCL Kenya 1 ERS549494 LN827563
78 sLCL-1.19 sLCL Kenya 1 ERS549495 LN827562
79 sLCL-BL1.20 sLCL Kenya 1 ERS549496 LN827571
80 sLCL-2.21 sLCL Kenya 2 ERS549497 LN827587
81 sLCL-2.22 sLCL Kenya 2 ERS549498 LN831023
82 sLCL-1.24 sLCL Kenya 1 ERS549499 LN827568
83 pLCL-TRL1-pre sLCL, PTLD USA 1 ERS074921 LN824207
84 pLCL-TRL1-post sLCL, PTLD USA 1 ERS074922 LN824206
85 pLCL-TRL595 sLCL, PTLD USA 1 ERS074924 LN827559
86 X50-7 LCL USA 1 ERS074942 LN827555
87 LCL B95-8 (del EBER2)
re-sequence
LCL B95-8, deleted
EBER2
USA 1 ERS549474 LN827739
a BL, Burkitt’s lymphoma; GC, gastric carcinoma; HL, Hodgkin’s lymphoma; IM, infectious mononucleosis; LCL, lymphoblastoid cell line; sLCL, spontaneous lymphoblastoid cell
line; NPC, nasopharyngeal carcinoma; PTLD, posttransplant lymphoproliferative disease; PNG, Papua New Guinea; N. Africa, North Africa.
b The Raji sequence was provided by Wolfgang Hammerschmidt prior to publication.
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FIG 1 Origin of samples and alignment of new EBV genome sequences. (A) World map depicting the origins of the 83 unique EBV genomes sequenced
and analyzed in this study. The sizes of the circles are proportional to the number of samples from each geographic region, with country and number of
genomes annotated. One sample without country information is listed as “African,” and one sample of unknown geographic origin is not shown. (B)
Whole-genome multiple-sequence alignment of all EBV genomes, including the EBV (B95-8/Raji) reference genome (NC_007605, top) and 12 previously
published genomes (annotated with a “P”). Strains are ordered by their similarity to the sequence of the type 1 reference strain (NC_007605), shown at
the top. Type 1 genomes are in blue, type 2 genomes are in red, and recombinant (type 1/2) sequences are in purple. Contigs are indicated in green. Repetitive
regions are masked out in gray. Gaps and deletions are in white. The wild-type genome derived from the saliva of a healthy individual is annotated with a turquoise
dot. The HL04 Hodgkin lymphoma biopsy specimen has an inversion of a section of the genome from position 65000 to 125000. Known deletions in Daudi,
P3HR1, pLCL-TRL1, and an LCL generated with a B95-8-based BAC (LCL delEBER2) were detected.
5226 jvi.asm.org May 2015 Volume 89 Number 10Journal of Virology
FIG 2 SNP variation across all EBV genomes. (A) Single nucleotide polymorphism (SNP) frequency across 83 unique EBV genomes. The line graph is plotted
across the genome showing the number of base positions in a sliding 1,000-nt window where at least one EBV sequence has a SNP relative to the consensus
sequence. Repeat regions are masked out in gray. (B) Mean number of codon changes (relative to the consensus of 83 EBV sequences) per gene across the genome,
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variant sites (GTRGI). A phylogenetic tree was generated using max-
imum likelihood implemented in PhyML (v3.0) (36). Tree topology was
assessed by bootstrapping analysis using 600 pseudoreplicates, and boot-
strap values above 60 are shown on the tree. The tree was rooted on the
longest branch.
Epitope variation and positive selection analysis. SNP variations
within previously identified T-cell epitopes (51) were called from multi-
ple-sequence alignments of the EBNA3A, -3B, and -3C protein sequences.
Sequences without an intact open reading frame were excluded, and re-
peat regions were masked in the alignment. Positive selection analysis was
performed using the Datamonkey web server of the HyPhy package (37,
38). Model selection was performed using jModelTest (v2.1.5) (35), and
recombination was screened for using GARD and SBP recombination
detection programs (39). Recombination was accounted for by using the
trees generated by GARD on either side of confirmed breakpoints. Posi-
tive selection was detected using the fixed-effects likelihood (FEL; P 
0.05), mixed-effects model of evolution (MEME; P 0.05), and fast un-
constrained Bayesian approximation (FUBAR; posterior probability 
0.9) methods (40–42), and codons were reported as under selection if they
were significant in two or more programs.
presented as codon changes per 1,000 amino acids to normalize for gene length. Synonymous nucleotide changes are indicated by blue bars and nonsynonymous
changes by red bars. The repeat regions within BZLF1, BPLF1, BLLF1, and EBNA1, -2, -3B, and -3C have been masked, and data are provided for the
nonrepetitive region only. The right scale shows the percentage of EBV genomes with an intact open reading frame for each gene. BWRF1, EBNA-LP, BHLF1, and
LF3 were incompletely assembled due to repetitive regions and were not determined. (C) Numbers of codon changes per gene (means standard errors of the
means, normalized per kilobase), separated into gene type. Latent genes have an increased number of changes compared to early and late lytic genes. Latency-
associated genes also have an increased ratio of nonsynonymous to synonymous coding changes compared to lytic genes.
TABLE 2 Variation in T-cell epitopes in EBNA3 genesa
Gene Epitope HLA allele Codons
No. of type 1
sequences with
conserved
epitope/total
Variation type 1 (no. of
sequences)
No. of type 2
sequences with
conserved
epitope/total
Variation type 2
(no. of sequences)
EBNA3A RRFPLDLR B27.05 95–102 67/67 0/16 R1Y (16)
QAKWRLQTL B8 158–166 67/67 0/16 QVKWRMTTL (16)
AYSSWMYSY A30 176–184 65/67 S3I (1), Y2F (1) 16/16
RYSIFFDY A24 246–253 66/67 R1C (1) 0/16 R1C (16)
FLRGRAYGL B8 325–333 61/67 L9I (3), L2F (1), A6V (1), F1L (1) 0/16 F1L,L9Q (16)
KRPPIFIRR B27.05 378–386 67/67 0/16 K1R,I7L (16)
RPPIFIRRL B7 379–387 67/67 0/16 I6L (16)
RRLHRLLLMR B27.05 386–395 67/67 16/16
HLAAQGMAY ND 450–458 65/67 A3E (1), M7K (1) 0/16 H——– (16)
YPLHEQHGM B35 458–466 22/67 P2T (20), H7R (11), H4K (9),
P2S (2), M9T (1), P2T (1),
P2R (1)
0/16 -PLHQQHSM (16)
VSSDGRVAC A29 491–499 44/67 R6Q (11), D4E (10), S2F (2) 0/16 VPKDGRGAC (16)
VPAPAGPIV B7 502–510 67/67 0/16 P4L (16)
SVRDRLARL A2 596–604 67/67 16/16
RLRAEAQVK A3 603–611 67/67 0/16 V8A,K9R (16)
VQPPQLTQV B46 617–625 33/67 P4T (32), L6V(1), V1E,Q2K (1) 0/16 P4T (16)
EBNA3B HRCQAIRKK B27.05 154–157 64/64 0/16 K8Q (16)
TYSAGIVQI A24 217–225 63/64 I9L (1) 0/16 I9L (16)
RRARSLSAERY B27.02 244–254 64/64 16/16
VSFIEFVGW B58 279–287 64/64 0/16 S2A,I4V (16)
AVFDRKSDAK A11 399–408 44/64 A1S,V2L (8), D4N (4), A1S (3),
A1P,V2L (2), A1S,V2F (2),
A1P (1)
0/16 SVFYRKPDTK (16)
IVTDFSVIK A11 416–424 37/64 K9N (13), V2L (9), K9R (1),
V2L,K9R (4),
0/16 F5L,V7I (16)
AVLLHEESM B35 488–496 43/64 A1T (21), 0/16 RVILHGPPT (16)
VEITPYKPTW B44 657–666 39/64 I3L (23), Y6D,K7E (2), ND, gap AG876 has VEPTFYQSTW
EBNA3C EGGVGWRHW B44 163–171 65/66 R7- (1) 16/16
LRGKWQRRYR B27.05 249–258 57/66 R7K (9) 0/16 Y9F (16)
RRIYDLIEL B27.0204.05 258–266 51/66 R2K (15) 0/16 Y4F (16)
EENLLDFVRF B44 281–290 66/66 15/16 R9H (1)
LLDFVRFMGV A2 284–293 66/66 15/16 V6H (1)
LDFVRFMGV B37 286–293 66/66 15/16 R5H (1)
KEHVIQNAF B44 335–343 57/66 E2D (5), H3Q (4) 0/16 H3Q,N7K (16)
FRKAQIQGL B27.05 343–351 49/66 I6L (13), I6 M (4) 0/16 R2L,I6R (16)
QPRAPIRPI B7 881–889 65/66 R3P (1) 16/16
a ND, not determined. Bold type indicates conservation in all samples.
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Principal-component analysis and recombination detection. Prin-
cipal-component analysis was performed on all SNPs in the genomes
using the scikit-learn package of ScientificPython (43). SimPlot
(v3.5.1) (44) and RDP4 (v4.35) (45) were used to detect recombina-
tion between strains. Similarity plots and bootscan analysis using a
window size of 4,000 and increment of 1,000 were generated using
manual bootscan in RDP4.
Data accession numbers. All sequence data are available in the Euro-
pean Nucleotide Archive (http://www.ebi.ac.uk/ena) under the study ac-
cession number ERP001026 and individual sample accession numbers as
listed in Table 1. All genome sequences are available in GenBank under the
accession numbers listed in Table 1.
RESULTS
Target enrichment, sequencing, and de novo assembly of EBV
genomes. The large (172-kb) EBV genome combined with the low
abundance of viral DNA relative to host DNA presents a sequenc-
ing challenge. A custom target enrichment library for EBV was
designed, comprising a series of 120-nucleotide RNA oligonucle-
otide baits tiled across the EBV genome (7,154 baits covering type
1 EBV and 7,193 covering type 2 EBV) (25). The EBV baits are
biotinylated, allowing selective capture of EBV DNA using
streptavidin-coated beads. Starting with 1 to 3 g of DNA, up to
2,000-fold enrichment of EBV DNA was achieved using this
method, with 70 to 85% of reads mapping to the EBV genome
after enrichment, compared to about 0.04% of reads without en-
richment. Multiplexing up to 25 enriched samples per lane of an
Illumina HiSeq sequencer produced sufficient 76-nt paired-end
reads from each sample to allow de novo assembly of the EBV
genome with an average coverage depth of1,000 reads per nu-
cleotide. A de novoEBV genome assembly pipeline was established
that does not use a reference sequence, thus avoiding bias that may
be introduced by reference-based read mapping. Seventy-one
novel EBV genomes and 3 previously sequenced strains were se-
quenced and assembled (Table 1). The novel EBV sequences were
from spontaneous lymphoblastoid cell lines (LCLs) from Austra-
lia and Kenya, Burkitt lymphoma cell lines, Hodgkin lymphoma
primary biopsy specimens and cell lines, NPC cell lines and biopsy
specimens, one gastric cancer cell line, and one EBV strain from
the saliva of a healthy individual. Combined with 12 published
EBV genome sequences, this resulted in a final data set of 83
unique EBV genomes (Table 1). A summary of the geographic
origins of the samples is shown in Fig. 1A.
All genomes were assembled into large contiguous DNA se-
quences (contigs) separated by the repeat regions, which were not
resolvable using short Illumina reads. Five regions required clos-
ing and validating by PCR and capillary sequencing, including
parts of LMP1 and EBNA2 (PCR primers are listed in Table SA1 in
the supplemental material). To assess the reproducibility of the
sequencing and analysis pipeline, DNA was extracted from the
same cell line on two occasions (Mak1 and Makau), and identical
EBV genome sequences were obtained (see Fig. SA1 in the supple-
mental material). Identical sequences were also obtained from
two cell lines established a few weeks apart from the same tumor
(pLCL-TRL1-pre and -post), in which a previously described
245-bp deletion in EBNA3B (46) was correctly identified. We also
resequenced EBV from the cell lines C666-1 and Akata, whose
EBV genomes have recently been published (20, 23), and a bacte-
rial artificial chromosome (BAC) containing the B95-8 genome.
Twenty-three, three, and three single nucleotide polymorphisms
(SNPs) between our data and the published genomes from
C666-1, Akata, and B95-8, respectively, were detected. This con-
trasts the typical several hundred nucleotide differences between
any two type 1 EBV genomes sequenced. The total number of
SNPs between each of the EBV genomes can be seen in detail in
Fig. SA1 in the supplemental material.
The EBV genome map is representative of cell line, tumor,
and wild-type saliva EBV genomes. Comparison of EBV contigs
to the B95-8/Raji reference sequence (NC_007605) showed that
most of the newly sequenced genomes were intact in all regions of
the genome (Fig. 1B). We observed the known deletions in a B95-8
derived LCL (LCL B95-8 del EBER2) (47) and in EBV genomes
from Daudi and P3HR1. Some EBV strains also had novel dele-
tions relative to the reference strain, including a deletion of ap-
proximately 10 kb in the BART region of the AFB1 LCL genome
sequence, overlapping but distinct from the deletion present in
the B95-8 reference sequence. One isolate from a primary Hodg-
kin lymphoma (HL04) had an inversion of a large part of the EBV
genome corresponding to approximately nucleotides 65000 to
125000 in the reference sequence, with large deletions at each end
of the inversion (Fig. 1B). Only 5/83 (6%) of the EBV genomes
studied here had such large-scale genome disruption.
The multiple-sequence alignment (Fig. 1B) and detailed gene-
by-gene analysis of all 83 EBV genomes strongly suggests that the
current EBV genome map annotated in NC_007605 is a good
representation of the EBV genome. Consistent with this, the open
reading frames were shown to be conserved (Fig. 2B). The EBV
genome Saliva1 is derived directly from saliva of a healthy carrier
and is the first wild-type EBV genome sequenced that was not
selected by immortalization of B cells or derived from a cancer cell
(Fig. 1B). The close agreement of this sequence to the NC_007605
reference sequence, with no additional insertions or deletions, in-
dicates that the standard EBV genome map is representative of
transmissible saliva strains of EBV. The closest EBV strain (based
on the fewest SNPs) to the saliva EBV was HKN19, a spontaneous
LCL from Hong Kong. Although the identities of the saliva donors
tested were anonymous, the panel did include some Asian donors,
so it is likely that this is the basis of the similarity.
To estimate the repeat copy number of the major internal re-
peat (IR1 or BamW repeats), the short reads from each sample
were mapped to a single reference copy of the repeat, and the
depth of sequence coverage in the repeat array was compared to
the depth of coverage in BALF5, a highly conserved unique region
of the EBV genome (see Materials and Methods). There was good
agreement between the IR1 copy number calculated by this read
depth-mapping approach and that from direct measurement of
the size of IR1 by restriction enzyme digestion and Southern blot-
ting in a panel of cell lines (see Fig. SA2a in the supplemental
material). IR1 varied in copy number from 2 to 9 by sequence
mapping, with the most frequent number of internal repeats being
5 or 6 (see Fig. SA2b in the supplemental material). Terminal
repeat copy numbers detected in LCL and BL lines are thought to
vary considerably; consistent with that, the average terminal re-
peat copy number determined by Southern blotting in a panel of
17 LCLs or BL cell lines was 7.2, with a standard deviation of 3.7
(data not shown).
Diversity in EBV genomes is variable across the genome and
is highest in latent genes. To determine which parts of the EBV
genome are the most diverse, the number of variant positions
within a 1,000-nt sliding window was calculated across all ge-
nomes (Fig. 2A). There was substantial variation in SNP frequency
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across the genome with the highest SNP frequencies correlating
with the position of latency-associated genes. The number of syn-
onymous and nonsynonymous codon changes per kilobase of se-
quence for each EBV gene were also calculated (Fig. 2B), excluding
the repeat arrays. The highest number of codon changes were
present in the latent genes EBNA2, EBNA3 family, and LMP1.
Other genes with high levels of variation include BDLF3 and
BLLF1, which encode glycoproteins gp150 and gp350/200, respec-
tively, BZLF1 (immediate early gene), BRRF2 (tegument), and
BNLF2a, which is involved in immune evasion. The EBNA3 gene
region (including upstream genes BLLF1 and -2), EBNA2, the
EBNA1 region (including BRRF2 and BKRF2), and the LMP1
region (including BNLF2a) had a greater ratio of nonsynonymous
to synonymous codon changes, suggesting that these genes are
FIG 3 Variation in T-cell epitopes in EBNA3 genes. Variation in known T-cell epitopes in EBNA3A (A), EBNA3B (B) and EBNA3C (C) genes across all 83 EBV
genomes. Graphs indicate the percentage of EBV genome sequences with the epitope fully conserved (blue) and the percentage of sequences that have each of the
variant sequences as a stacked histogram. Some epitopes are fully conserved across all strains (fully blue bars), some have differences only between type 1 and type
2 (underlined), and some have multiple variants. Only sequences with an intact open reading frame were included.
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evolving under positive selection. Separating genes into latency
associated, early lytic, and late lytic showed a clear increase in SNP
frequency in latency-associated genes compared to lytic genes and
also an increased ratio of nonsynonymous to synonymous codon
changes in latency-associated genes (Fig. 2C).
EBNA3 CD8 T-cell epitope variation. EBV latency-associated
genes (particularly the EBNA3s) are targets of immune recogni-
tion during persistent infection, which has been proposed to ex-
plain the greater extent of nonsynonymous variation in these
genes (48, 51). We therefore examined the known CD8 T-cell
epitopes present in the EBNA3 gene cluster (48, 51), listed in Table
2. Two epitopes in EBNA3A (RRLHRLLLMR and SVRDRLARL)
were fully conserved across all sequenced genomes (Fig. 3A) and a
further six epitopes (RRFPLDLR, QAKWRLQTL, KRPPIFIRR,
RPPIFIRRL, VPAPAGPIV, RLRAEAQVK) were variant between
type 1 and type 2 sequences but fully conserved within each type
(underlined in Fig. 3A). The remaining seven epitopes each had
multiple variants present at different frequencies across the data
set (Fig. 3A). Similar patterns were seen in EBNA3B (Fig. 3B) and
EBNA3C (Fig. 3C), with some epitopes being conserved and some
highly variant. In EBNA3B, the immunodominant epitopes AVF
DRKSDAK and IVTDFSVIK (12) were the most diverse (Fig. 3B).
In general, epitopes were highly conserved within type 2 viruses,
with all epitopes being identical to AG876 in all type 2 strains with
the exception of EBNA3C epitopes in Wewak1 (one of only two
non-African type 2 viruses sequenced). A complete list of all
epitope variation is shown in Table 2.
Positive-selection analysis on the three EBNA3 genes detected
several codons under positive selection in each gene. The codons
of the EBNA3 coding regions found to be under positive selection
(Table 3) were nearly all located outside the established CD8 T-
cell epitopes listed in Table 2. Only 1 of 4 codons in EBNA3A, 3 of
12 in EBNA3B, and 0 of 3 in EBNA3C were within known T-cell
epitopes. This observation may suggest additional T-cell epitopes
yet to be discovered (perhaps related to major histocompatibility
complex [MHC] types that have not been studied yet), or these
codons might be under positive selection for other reasons, per-
haps related to the function of the EBNA3 genes.
LMP1 variation. Variation in the EBV latency-associated gene
LMP1 has been described in detail. Immortalized B-cell LCLs, B
cells in posttransplant lymphoproliferative disease, and the Reed
Sternberg cells of EBV-associated Hodgkin lymphoma all express
LMP1 at a high level. LMP1 is also expressed at a low level in NPC
and gastric cancers (49). Focusing mainly on its relevance to NPC
in China and some other parts of the world, LMP1 variants have
previously been classified into seven groups named NC (North
Carolina), Med, Alaskan, B95-8, China 1, China 2, and China 3,
based on the geographic origins of the original samples (16). A
phylogenetic tree of the LMP1 nucleotide sequences from the new
EBV sequences determined in this study and previously published
genome sequences shows that 6 of the 7 LMP1 types are present,
with no observation of the China 3 group. Five genomes have a
combination of two LMP1 types (Fig. 4). There is a good corre-
spondence between the LMP1 groups and the LMP1 phylogenetic
tree of this larger collection of EBV genomes, with the exception of
the China 1 group, which separates into several clades. We also
mapped type 2 EBNA2 or EBNA3 onto this analysis. Overall, there
is little correlation of LMP1 subtype with the type 1/2 designation
of the EBNAs, but it is noticeable that no type 2 EBNA genes are
present in viruses with the NC or Med forms of LMP1, even
though many of these genomes were from sub-Saharan Africa,
where type 2 EBV is most prevalent. It is clear that the NC and Med
forms of LMP1 can come from a wide range of geographic regions,
suggesting an exclusion of type 2 EBNA2 or EBNA3 in the ge-
nomes with NC or Med LMP1. This should be investigated further
in larger and more geographically diverse sample sets.
Type 1 and type 2 classification is a major feature of EBV
diversity and is defined by EBNA2 and EBNA3s. To identify the
major features of variation throughout the genome, we performed
principal-component analysis (PCA) on SNPs in the genomes.
Principal component 1 (PC1) separated EBV strains clearly into
type 1 and type 2 (Fig. 5A) and was the single greatest contributor
(14% of the variance) to separating the strains. Principal compo-
nents 2 and 3 provided further discrimination (6% and 6%, re-
spectively) between strains, explained in part by variation associ-
ated with geographic origin of the samples (Fig. 5B; strain names
are colored by geographic origin). Strains from Asia (blue) clus-
tered separately from other geographic locations, and some other
clusters were entirely of African origin. The parts of the EBV ge-
nome that contribute to the first three principal components are
shown in Fig. 5C. As expected, EBNA2 and EBNA3s account for a
large part of PC1 (type 1/type 2), but several genome regions,
including LMP1, distinguish PC2. PC3 is more evenly distributed
across the genome.
To test the contribution of EBNA2 to the type 1/type 2 desig-
nation, we removed the EBNA2 sequence from the genome align-
ment for all strains and reexamined the PCA. The dominant prin-
cipal component still showed clustering of strains based on type 1
and type 2 (see Fig. SA3a in the supplemental material), but re-
TABLE 3 EBNA3 amino acids under positive selection
Gene Codon
No. of
methodsa
Amino acid(s)
Location within
known epitopeReference Alternate
EBNA3A 54 2 H Q, P No
459 3 P T, S, R 458–466,
YPLHEQHGM
681 3 V A, M No
814 3 G V, A, D, T No
EBNA3B 33 2 T Q, K No
212 3 T M, L, R No
417 2 V L 416–424,
IVTDFSVIK
424 2 K N, R 416–424,
IVTDFSVIK
488 3 A T, R 488–496,
AVLLHEESM
553 3 P L, H No
614 3 R W, Q, L, P No
738 2 R Q No
847 3 A E No
887 2 A P, G, V No
899 3 G S No
900 3 Q K, R No
EBNA3C 104 3 T A, P No
215 2 A G, E No
357 2 G V, I No
a Positive-selection detection methods used were FEL, MEME, and Fubar using the
HyPhy package.
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moving both EBNA2 and the EBNA3 genes eliminated the type 1
and type 2 clustering as the major feature of variation (see Fig.
SA3b in the supplemental material). This shows that type 1/type 2
classification, the major feature of variation in EBV genomes, is
almost entirely dependent on EBNA2 and the EBNA3s. Further
analysis of PC2 and PC3 (see Fig. SA3c in the supplemental mate-
rial; colored by LMP1 type) shows that, although LMP1 variation
is a significant contributor to PC2 (Fig. 5C), strains do not clearly
separate by LMP1 type, and other points of variation in PC2 along
the genome also play a role. These genome-scale views of variation
show that the saliva-derived virus genome clusters with the EBV
type 1/Asian/China 1 LMP1 groups, further indicating the geo-
graphic origin of this virus.
Recombination between EBV strains. The established type 1
and type 2 EBV sequence types are normally defined by the
EBNA2 sequence, but a small number of intertypic recombinants
have been reported (11, 13). Two of the 83 strains analyzed here
appear to be intertypic recombinants. BL36, an African Burkitt
FIG 4 LMP1 phylogenetic tree classified by LMP1 type. Maximum-likelihood phylogenetic tree of LMP1 nucleotide sequence from 83 EBV strains (71 new
strains and 12 published strains, annotated with a “P”). Bootstrap values above 60 are shown, and the scale bar represents 0.01 nucleotide substitution per site.
All strains could be classified into one of the 7 LMP1 types (as defined in reference 16; see the key for colors), and these define the major clades of the tree, except
China 1 strains, which are split across several clades. Strains with type 2 EBNA2 and EBNA3 (empty red bars) are present in multiple LMP1 types but absent from
the NC and Med LMP1 types. Geographic origin (shown by the color of the sample name: blue, Asia; green, Africa; red, Europe; yellow, USA; purple, Australia;
dark red, Papua New Guinea) shows that many of the LMP1 types, including Med and NC, are found in strains from a wide geographic area.
Palser et al.
5232 jvi.asm.org May 2015 Volume 89 Number 10Journal of Virology
Genome Diversity of Epstein-Barr Virus
May 2015 Volume 89 Number 10 jvi.asm.org 5233Journal of Virology
lymphoma cell line and sLCL 1.18, a spontaneous LCL from Ke-
nya, encoded type 1 EBNA2 and type 2 EBNA3 sequences. Diver-
sity plots generated across the genome between sLCL 1.18 and the
type 1 (NC_007605) and type 2 (AG876, NC_009334) reference
sequences revealed that in the region corresponding to EBNA2
(around positions 36000 to 37000) there are few SNPs relative to
B95-8 but a large peak in the SNPs relative to AG876, indicating a
type 1 EBNA2 (Fig. 6A). Conversely, there was a high degree of
similarity to AG876 in the region corresponding to the EBNA3
genes (around positions 80000 to 89000) and a peak of SNPs rel-
ative to B95-8, indicating type 2 EBNA3 genes. No virus strains
with type 2 EBNA2 and type 1 EBNA3s were detected in this set of
genomes, consistent with previous studies (11, 13), although this
may constitute a sampling bias, as type 1 EBNA2 is more efficient
for B-cell transformation in vitro.
Extensive recombination in herpes simplex virus 1 was recently
described (50). The 83 EBV genomes were therefore examined for
the presence of intratypic recombination using RDP4 and
bootscanning analysis. Evidence for recombination appeared to
be extensive, so analysis was focused on geographically con-
strained genomes as defined by PCA (Fig. 5B), for example, type 1
EBV sequences from Asia (Fig. 6B). A diversity plot of the number
of SNPs between strain HKN19 and 4 other strains from the same
geographic region shows that the genome of HKN19 up to ap-
proximately position 80000 is very similar to that of EBV strain
D3201.2 and from approximately position 130000 is very similar
to that of EBV strain C666-1 (Fig. 6B, top). Other regions of the
genome show high similarity to strains YCCEL1 and Akata.
Bootscan analysis supported this conclusion (Fig. 6B, bottom)
and provided evidence for multiple recombination events be-
tween EBV genomes. The existence of such recombination should
be considered in any phylogenetic analysis of EBV sequence data.
Much greater sampling depth, with a more comprehensive and
strategic geographical sampling, would be needed to examine the
full extent of recombination in EBV genomes worldwide and the
contribution this makes to EBV diversity and disease associations.
DISCUSSION
Genetic analysis of whole virus genomes is essential to understand
virus transmission patterns, virus phenotypes, and disease-associ-
ated genotypes, although this has not been used extensively in
large DNA viruses. Here, we report the sequencing of 71 new EBV
genomes, including the first EBV genome sequenced directly from
saliva, and analyzed these in combination with 12 previously pub-
lished strains. This analysis revealed that the established gene map
of the EBV genome (NC_007605) is representative of EBV isolates
from different parts of the world and from different types of in-
fection. The well-established type 1/type 2 classification was reex-
amined with the 83 EBV genomes analyzed here and remains the
major form of variation, mostly accounted for by variation in
EBNA2 and EBNA3A, -B, and -C. In these 83 genomes, there was
type-specific linkage between type 2 EBNA2 and type 2 EBNA3
genes (12 strains) and type 1 EBNA2 and type 1 EBNA3 genes (69
strains). There were 2 cases of intertypic recombinants, both with
type 1 EBNA2 but type 2 EBNA3 genes. Since most EBV genomes
sequenced here are from B cells and type 1 EBNA2 is associated
with more efficient B-cell transformation, the overall incidence of
intertypic recombinants may be higher due to the possibility of
undetected EBNA2 type 2 and EBNA3 type 1 recombinants.
Whole-genome recombination analysis was performed on
samples from distinct geographic regions only. We observed in-
tratypic recombination between samples from the same geo-
graphic region with breakpoints present throughout the genome,
consistent with examples of intratypic recombinants described in
EBNA3 genes (3, 51) and a genome-wide study of 20 HSV strains
(50). The extent of recombination and the extreme differences in
SNP density between the latency-associated and structural genes
make phylogenetic trees of large regions of the genome difficult to
interpret and prevent the accurate identification of the ancestry of
strains at this stage. Such recombination in alpha and gamma
human herpesviruses suggests that reinfection (and indeed coin-
fection of single cells) must occur and that adaptive immunity is
not sufficient to prevent this. Whether this will affect herpesvirus
vaccine efficacy or provide an environment for vaccine and wild-
type herpesvirus recombination should be investigated. As with
RNA viruses, it is clear that much larger studies encompassing
EBV genome sequences from different locations worldwide and
from different disease associations will be required to identify
structural variants or mutations that may be associated with EBV
disease phenotypes.
A limitation of the target enrichment approach used here is
that the EBV bait design used the sequence of the B95-8 and
AG876 reference genomes. Thus, any novel sequence present in an
isolate might not be captured by the sequencing process. How-
ever, there is no specific evidence for this at this stage. If such novel
sequences were indeed present, they would appear as unclosable
gaps between contigs, but in fact, the only such gaps observed
could be accounted for by the presence of repeat regions. As with
all short-read sequencing, we did not obtain a unique assembly
across the repeat arrays present in the EBV genome; therefore, the
genomes are in effect large contigs of assembled sequence sepa-
rated by the large repeat regions. It should be noted that in previ-
ous studies of single EBV genome sequences, presented as com-
plete genomes, a suitable number of identical copies of the repeat
elements were inserted to provide a continuous sequence without
evidence of the number of copies or that all copies are identical.
We have chosen to leave such regions as unassigned, but we have
shown that correlating variation in read depth from a repeat re-
gion relative to a unique region does provide an accurate way to
estimate the repeat copy number for the EBV major internal re-
peat (IR1). A detailed analysis of IR1 repeat variation will be re-
ported separately.
There is clear evidence for a higher frequency of SNPs in laten-
cy-associated genes and also a higher ratio of nonsynonymous
changes. This may be consistent with positive selection in these
genes, perhaps in relation to MHC types, as has been proposed
FIG 5 Principal-component analysis separates strains by type 1/2 and geographic origin. Principal-component analysis (PCA) of all EBV strains (71 new strains
and 12 published strains, annotated with a “P”) based on SNPs relative to the consensus sequence in a full-genome multiple-sequence alignment. (A) Principal
component 1 separates all strains based on type 1 and type 2, with all type 2 strains (triangles) clustering together (including two intertypic recombinants, BL36
and sLCL-1.18, which have type 2 EBNA3s). (B) Principal component 2 shows some geographic clustering of EBV strains, with clear separation of the Asian
strains (blue). (C) Regions of the EBV genome that contribute to the first three principal components.
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FIG 6 Recombination between different EBV strains. (A) Intertypic recombination between type 1 and type 2 EBV strains. Diversity plots show the number of
SNPs per 1,000-nt sliding window comparing EBV strain sLCL-1.18 with the type 1 reference genome (NC_007605; blue) and the type 2 reference genome
(AG876; red). Major repeat regions are masked out (vertical gray bars). The sLCL-1.18 EBV genome is highly similar to the type 1 genome in the EBNA2 region
(around positions 36000 to 37000) and highly similar to type 2 in the EBNA3s region (around positions 80000 to 89000). (B) Evidence for recombination between
different type 1 EBV strains. Diversity and bootscan plots comparing strain HKN19 with 4 geographically related (southeast Asian) EBV strains, with repeat
regions masked out (gray bars). Diversity plots (top; number of SNPs in a 1,000-nt sliding window) show high levels of similarity (few SNPs) between HKN19
and strain D3201.2 until approximately position 80000 and similarity to other strains in other parts of the genome. Bootscan plots (bottom) of the same strains
confirm that clustering of the strains changes across the genome, indicating the presence of multiple recombination events throughout the genomes.
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previously (12, 48). However, most of the codons in EBNA3 genes
that were under positive selection were not in known cytotoxic-
T-lymphocyte (CTL) epitopes, suggesting either that many more
epitopes remain to be discovered or that selection is on other
functional features of the EBNA3 proteins (52). There was similar
evidence for a higher frequency of nonsynonymous changes in
glycoproteins, including gp350 and gp25, which have both been
shown to be CTL targets, and the immune evasion gene BNLF2a
(Fig. 2B). It is notable that there is a clustering of genes with a high
ratio of nonsynonymous changes in certain genome regions, but
the reason for this is unclear. The further definition of CTL
epitope diversity will have an important impact on CTL immuno-
therapies that are being assessed to treat an increasing range of
EBV-associated malignancies.
In addition to its importance for design of an EBV vaccine,
describing the sequence variation of the EBV genome is essential
for identifying the role of variation in diseases associated with
EBV, particularly diseases whose incidence varies in different geo-
graphic locations. For example, for NPC in Southeast Asia, genetic
variation of the host, local environmental cofactors (including
coinfections), and natural variation in EBV are likely to be impor-
tant. Our results show that there are many points of variation that
distinguish Asian strains of EBV from EBV from other parts of the
world; indeed, PC2 in our principal-component analysis corre-
sponds to some extent with the Asian EBV strains. It may be that
the endemic strain of EBV in Southern China is inherently more
able to contribute to NPC, and it is still possible that a specific EBV
variant is involved in that cancer. The recent demonstration (53)
of the importance of a single amino acid in EBNA2 for determin-
ing the superior growth maintenance function of type 1 EBNA2
shows how very small sequence differences can have a large effect
on phenotype in EBV. Our results provide the first global view of
EBV sequence variation at the whole-genome level, validate the
currently used genetic map, demonstrate an effective method for
sequencing large numbers of virus genomes, and create a frame-
work for much larger future studies directed to these goals.
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